Related Experiment Video
Updated: Sep 25, 2026
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
Published on: April 18, 2025
Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A
Daniela Cecconi1, Aldo Scarpa, Massimo Donadelli
1Department of Agricultural and Industrial Biotechnologies, University of Verona, Verona, Italy.
Abstract:
A pancreatic adenocarcinoma cell line (Paca44) was treated with trichostatin-A (TSA), a potent inhibitor of histone deacetylases, in order to evaluate the effect of this drug on protein expression. Master maps of control and treated Paca44 cells were generated by analysis with the PDQuest software. The comparison between such maps showed up- and downregulation of 51 polypeptide chains, out of a total of 700 spots detected by a medium-sensitivity stain, micellar Coomassie Brilliant Blue. Fingerprinting by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF)-mass spectrometry analysis enabled the identification of 22 of these spots. Among these proteins, of particular interest are the two downregulated proteins nucleophosmin and translationally controlled tumor protein, as well as the upregulated proteins programmed cell death protein 5 (also designated as TFAR19) and stathmin (oncoprotein 18). The modulation of these four proteins is consistent with our observation that TSA is able to inhibit cell growth of Paca44 by causing cell cycle arrest at the G2 phase and apoptotic cell death.
Insights
Trichostatin-A (TSA) treatment of pancreatic cancer cells altered protein expression, downregulating nucleophosmin and translationally controlled tumor protein while upregulating programmed cell death protein 5 and stathmin. This suggests TSA inhibits cancer cell growth via cell cycle arrest and apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Pancreatic adenocarcinoma is a lethal malignancy with limited treatment options.
- Histone deacetylase inhibitors, such as trichostatin-A (TSA), are emerging as potential therapeutic agents.
- Understanding TSA's effects on protein expression is crucial for its clinical application.
Purpose of the Study:
- To investigate the impact of trichostatin-A (TSA) on protein expression in pancreatic adenocarcinoma cells (Paca44).
- To identify specific proteins modulated by TSA treatment.
- To correlate protein expression changes with observed effects on cell growth and cell cycle.
Main Methods:
- Pancreatic adenocarcinoma cell line (Paca44) treated with trichostatin-A (TSA).
- Proteomic analysis using PDQuest software and micellar Coomassie Brilliant Blue staining.
- Protein identification via matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF)-mass spectrometry.
Main Results:
- TSA treatment resulted in the differential expression of 51 polypeptide chains out of 700 detected spots.
- Key identified proteins with altered expression include downregulated nucleophosmin and translationally controlled tumor protein.
- Upregulated proteins of interest were programmed cell death protein 5 (TFAR19) and stathmin (oncoprotein 18).
Conclusions:
- TSA significantly modulates protein expression in pancreatic adenocarcinoma cells.
- The observed protein changes, particularly in nucleophosmin, translationally controlled tumor protein, programmed cell death protein 5, and stathmin, are consistent with TSA's anti-cancer effects.
- TSA inhibits Paca44 cell growth by inducing G2 phase cell cycle arrest and apoptotic cell death.
